Search results for "Osteoporosis"


 
Results 1 - 10 of about 141 for "Osteoporosis".
Sort by: Relevance | Newest | Oldest

Antifracture effects of zoledronate persist for up to 3.5 years, study suggests

Fracture rates rose from 15 per 1,000 woman-years in the last two years of a six-year trial to 24 fractures in the first two years of follow-up. In the next two years of follow-up, the rate substantially increased to 42 fractures per 1,000 woman-years.
https://immattersacp.org/weekly/archives/2024/03/12/4.htm
12 Mar 2024

CPAP masks with magnets recalled

This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2024/03/cpap-masks-with-magnets-recalled.htm
1 Mar 2024

Testosterone may not decrease fracture risk in hypogonadism

A substudy of an industry-funded randomized trial in men with hypogonadism found that 3.50% of those assigned to testosterone and 2.46% assigned to placebo had a clinical fracture after 3.19 years of follow-up.
https://immattersacp.org/weekly/archives/2024/01/23/2.htm
23 Jan 2024

Latest updates on ACP's priorities, initiatives

ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, ACP Internist Weekly.
https://immattersacp.org/archives/2023/11/latest-updates-on-acps-priorities-initiatives.htm
1 Nov 2023

New ACP paper reviews performance measures for osteoporosis

Of the six osteoporosis performance measures relevant to internal medicine physicians, only one is valid at three levels of attribution, i.e., individual physician, group practice, and health plan, an ACP assessment found.
https://immattersacp.org/weekly/archives/2023/10/10/6.htm
10 Oct 2023

OTC birth control pill, naloxone gain approval

This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2023/09/otc-birth-control-pill-naloxone-gain-approval.htm
1 Sep 2023

Cardiovascular effects of vitamin D supplementation still uncertain, trial finds

Older adults who were randomized to vitamin D supplementation had a slightly lower rate of cardiovascular events, particularly myocardial infarction, but the overall difference from placebo was not significant, an Australian trial found.
https://immattersacp.org/weekly/archives/2023/07/04/4.htm
4 Jul 2023

Be on alert for blood cancer precursors

Joseph R. Mikhael, MD, FACP, reviewed practical approaches to two premalignant conditions, monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL).
https://immattersacp.org/archives/2023/07/be-on-alert-for-blood-cancer-precursors.htm
1 Jul 2023

MKSAP Quiz: Risks of gender dysphoria treatment

A 37-year-old transgender woman (genetic male, identifies as a female) requests feminizing hormone therapy. She was diagnosed with gender dysphoria by her psychiatrist in accordance with DSM-5 criteria. Following lab studies, what treatment risks should be reviewed with the patient?
https://immattersacp.org/weekly/archives/2023/06/06/3.htm
6 Jun 2023

Closing the gap on osteoporosis

A new clinical guideline from ACP focuses on pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults.
https://immattersacp.org/archives/2023/05/closing-the-gap-on-osteoporosis.htm
1 May 2023

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next